Said J W, Hoyer K K, French S W, Rosenfelt L, Garcia-Lloret M, Koh P J, Cheng T C, Sulur G G, Pinkus G S, Kuehl W M, Rawlings D J, Wall R, Teitell M A
Department of Pathology, University of California at Los Angeles School of Medicine, 90095-1732, USA.
Lab Invest. 2001 Apr;81(4):555-64. doi: 10.1038/labinvest.3780264.
Activation of the TCL1 oncogene has been implicated in T cell leukemias/lymphomas and recently was associated with AIDS diffuse large B cell lymphomas (AIDS-DLBCL). Also, in nonmalignant lymphoid tissues, antibody staining has shown that mantle zone B cells expressed abundant Tcl1 protein, whereas germinal center (GC; centrocytes and centroblasts) B cells showed markedly reduced expression. Here, we analyze isolated B cell subsets from hyperplastic tonsil to determine a more precise pattern of Tcl1 expression with development. We also examine multiple B cell lines and B lymphoma patient samples to determine whether different tumor classes retain or alter the developmental pattern of expression. We show that TCL1 expression is not affected by Epstein-Barr virus (EBV) infection and is high in naïve B cells, reduced in GC B cells, and absent in memory B cells and plasma cells. Human herpesvirus-8 infected primary effusion lymphomas (PEL) and multiple myelomas are uniformly TCL1 negative, whereas all other transformed B cell lines tested express moderate to abundant TCL1. This observation supports the hypothesis that PEL, like myeloma, usually arise from post-GC stages of B cell development. Tcl1 protein is also detected in most naïve/GC-derived B lymphoma patient samples (23 of 27 [85%] positive), whereas most post-GC-derived B lymphomas lack expression (10 of 41 [24%] positive). These data indicate that the pattern of Tcl1 expression is distinct between naïve/GC and post-GC-derived B lymphomas (P < 0.001) and that the developmental pattern of expression is largely retained. However, post-GC-derived AIDS-DLBCL express TCL1 at a frequency equivalent to naïve/GC-derived B lymphomas in immune-competent individuals (7 of 9 [78%] positive), suggesting that TCL1 down-regulation is adversely affected by severe immune system dysfunction. These findings demonstrate that TCL1 expression in B cell lymphoma usually reflects the stage of B cell development from which they derive, except in AIDS-related lymphomas.
TCL1癌基因的激活与T细胞白血病/淋巴瘤有关,最近还与艾滋病弥漫性大B细胞淋巴瘤(AIDS-DLBCL)相关。此外,在非恶性淋巴组织中,抗体染色显示套区B细胞表达丰富的Tcl1蛋白,而生发中心(GC;中心细胞和中心母细胞)B细胞的表达则明显降低。在此,我们分析了来自增生性扁桃体的分离B细胞亚群,以确定Tcl1随着发育表达的更精确模式。我们还检测了多个B细胞系和B淋巴瘤患者样本,以确定不同肿瘤类别是否保留或改变了表达的发育模式。我们发现TCL1的表达不受爱泼斯坦-巴尔病毒(EBV)感染的影响,在未成熟B细胞中表达较高,在GC B细胞中表达降低,在记忆B细胞和浆细胞中不表达。人类疱疹病毒8感染的原发性渗出性淋巴瘤(PEL)和多发性骨髓瘤均为TCL1阴性,而所有其他检测的转化B细胞系均表达中度至丰富的TCL1。这一观察结果支持了这样的假设,即PEL与骨髓瘤一样,通常起源于B细胞发育的GC后阶段。在大多数未成熟/GC来源的B淋巴瘤患者样本中也检测到Tcl1蛋白(27例中有23例[85%]呈阳性),而大多数GC后来源的B淋巴瘤缺乏表达(41例中有10例[24%]呈阳性)。这些数据表明,未成熟/GC来源和GC后来源的B淋巴瘤之间Tcl1的表达模式不同(P < 0.001),且表达的发育模式在很大程度上得以保留。然而,GC后来源的AIDS-DLBCL在免疫功能正常个体中的TCL1表达频率与未成熟/GC来源的B淋巴瘤相当(9例中有7例[78%]呈阳性),这表明TCL1的下调受到严重免疫系统功能障碍的不利影响。这些发现表明,B细胞淋巴瘤中的TCL1表达通常反映了它们所源自的B细胞发育阶段,但艾滋病相关淋巴瘤除外。